Related Experiment Video

Updated: Jul 21, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer

Triantafillos Liloglou1, Matthew Walters, Paul Maloney

  • 1Molecular Oncology Unit, Roy Castle International Centre for Lung Cancer Research, 200 London Road, Liverpool L3 9TA, United Kingdom.

Lung Cancer (Amsterdam, Netherlands)
|July 26, 2002
PubMed

Insights

Researchers identified a new GSTM4 gene polymorphism, potentially increasing lung cancer risk. This finding suggests a new avenue for understanding genetic predispositions to lung cancer.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • Human Glutathione S-Transferases (GSTs) are phase II enzymes crucial for detoxifying carcinogens.
  • While GSTM1 polymorphisms are linked to cancer, GSTM4 polymorphisms remain unstudied.
  • GSTM4 plays a role in cellular detoxification pathways.

Purpose of the Study:

  • To identify and characterize polymorphisms in the GSTM4 gene.
  • To investigate the association between a novel GSTM4 polymorphism and lung cancer risk.

Main Methods:

  • Gene sequencing to identify polymorphisms in the GSTM4 gene.
  • Case-control study comparing allele frequencies in lung cancer patients and healthy controls.
  • Statistical analysis including odds ratios and Fisher's exact test.

Main Results:

  • A new C-T polymorphism in intron 6 of GSTM4 (T2517C) was identified, designated alleles *A (T) and *B (C).
  • The *B allele was less frequent in lung cancer patients (12/163) than in healthy controls (23/156).
  • Carriage of the *B allele showed a statistically significant association with reduced lung cancer risk (O.R.=2.23, P=0.026), indicating allele *A may increase risk. No association with tumor type, gender, or age was found.

Conclusions:

  • This study reports the first identified polymorphism in the GSTM4 gene.
  • The identified GSTM4 polymorphism (*B allele) may be associated with a decreased risk of lung cancer.
  • Further research is needed to confirm these findings and elucidate the mechanism.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...